- Home
- Publications
- Publication Search
- Publication Details
Title
A journey through infectious risk associated with ruxolitinib
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-08-30
DOI
10.1111/bjh.16174
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tuberculosis and atypical mycobacterial infections in ruxolitinib treated patients with primary or secondary myelofibrosis or polycythemia vera
- (2019) Sylvain Lescuyer et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis
- (2019) Mads Emil Bjørn et al. LEUKEMIA & LYMPHOMA
- Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
- (2019) Georg Maschmeyer et al. LEUKEMIA
- Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment
- (2018) Harinder Gill et al. ANNALS OF HEMATOLOGY
- Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine
- (2018) Stephanie F. James et al. ANNALS OF PHARMACOTHERAPY
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
- (2018) M. Reinwald et al. CLINICAL MICROBIOLOGY AND INFECTION
- Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
- (2018) Nicola Polverelli et al. HEMATOLOGICAL ONCOLOGY
- Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature
- (2018) Yasuhiro Tsukamoto et al. INTERNAL MEDICINE
- Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease
- (2018) Badri Modi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Studies with herpes zoster vaccines in immune compromised patients
- (2017) Myron J. Levin et al. Expert Review of Vaccines
- Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
- (2017) Rohit Loomba et al. GASTROENTEROLOGY
- Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
- (2017) Francesca Palandri et al. HEMATOLOGICAL ONCOLOGY
- The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms
- (2017) Gabriela S. Hobbs et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Inflammation and myeloproliferative neoplasms
- (2017) Federico Lussana et al. JOURNAL OF AUTOIMMUNITY
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors
- (2017) Christina Gavegnano et al. PLoS Pathogens
- The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature
- (2017) Maria Veronica Dioverti et al. Infectious Diseases
- Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib
- (2016) Benoit Branco et al. ANNALS OF HEMATOLOGY
- Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
- (2016) William Vainchenker et al. BLOOD
- Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
- (2016) R. Das et al. BLOOD
- Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice
- (2016) Sophia Maschalidi et al. BLOOD
- The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)
- (2016) Ruben Mesa et al. BRITISH JOURNAL OF HAEMATOLOGY
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib
- (2016) Keita Kirito et al. INTERNAL MEDICINE
- The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK
- (2016) J Rudolph et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm
- (2016) Jen Chin Wang et al. LEUKEMIA RESEARCH
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)
- (2015) Michael Sandherr et al. ANNALS OF HEMATOLOGY
- JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms
- (2015) Sowmya Parampalli Yajnanarayana et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells
- (2015) Clodagh Keohane et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
- (2015) Kathrin Schönberg et al. CANCER RESEARCH
- American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
- (2015) K. Rajender Reddy et al. GASTROENTEROLOGY
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study
- (2015) Malin Hultcrantz et al. JOURNAL OF CLINICAL ONCOLOGY
- Varicella zoster virus immunity: A primer
- (2015) Christopher J.A. Duncan et al. JOURNAL OF INFECTION
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
- (2015) R Zeiser et al. LEUKEMIA
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge
- (2014) Francesca Palandri et al. ANNALS OF HEMATOLOGY
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
- (2014) S. Spoerl et al. BLOOD
- Disseminated tuberculosis associated with ruxolitinib
- (2014) R K Hopman et al. LEUKEMIA
- Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis
- (2014) Yen-Hao Chen et al. LEUKEMIA & LYMPHOMA
- An Immune Dysregulation in MPN
- (2014) Giovanni Barosi Current Hematologic Malignancy Reports
- TUBERCULOSIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES
- (2014) Luis Anibarro et al. Mediterranean Journal of Hematology and Infectious Diseases
- Hepatitis B virus reactivation associated with ruxolitinib
- (2013) Chien-Heng Shen et al. ANNALS OF HEMATOLOGY
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
- (2013) M Massa et al. LEUKEMIA
- Autoimmunity and the risk of myeloproliferative neoplasms
- (2010) S. Y. Kristinsson et al. HAEMATOLOGICA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poor concordance between interferon-γ release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals
- (2009) Naasha J Talati et al. BMC INFECTIOUS DISEASES
- Risks of myeloid malignancies in patients with autoimmune conditions
- (2009) L A Anderson et al. BRITISH JOURNAL OF CANCER
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now